RU2007112876A - Модифицированные белки, сконструированные токсины и способы их получения - Google Patents

Модифицированные белки, сконструированные токсины и способы их получения Download PDF

Info

Publication number
RU2007112876A
RU2007112876A RU2007112876/13A RU2007112876A RU2007112876A RU 2007112876 A RU2007112876 A RU 2007112876A RU 2007112876/13 A RU2007112876/13 A RU 2007112876/13A RU 2007112876 A RU2007112876 A RU 2007112876A RU 2007112876 A RU2007112876 A RU 2007112876A
Authority
RU
Russia
Prior art keywords
immunotoxin
cell
antibody
malignant
scfvmel
Prior art date
Application number
RU2007112876/13A
Other languages
English (en)
Other versions
RU2432358C2 (ru
Inventor
Майкл Г. РОЗЕНБЛЮМ (US)
Майкл Г. РОЗЕНБЛЮМ
Лоренс ЧЕУНГ (US)
Лоренс ЧЕУНГ
Original Assignee
Рисерч Дивелопмент Фаундейшн (US)
Рисерч Дивелопмент Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рисерч Дивелопмент Фаундейшн (US), Рисерч Дивелопмент Фаундейшн filed Critical Рисерч Дивелопмент Фаундейшн (US)
Publication of RU2007112876A publication Critical patent/RU2007112876A/ru
Application granted granted Critical
Publication of RU2432358C2 publication Critical patent/RU2432358C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Claims (17)

1. Способ лизиса злокачественной клетки, предусматривающий обеспечение этой клетке эффективного количества иммунотоксина, содержащего коровую область токсина гелонина и одноцепочечное антитело, которое специфически нацелено на эту злокачественную клетку.
2. Способ по п.1, где иммунотоксин содержит SEQ ID NO:1.
3. Способ по п.1, где антитело нацелено на опухолевый антиген.
4. Способ по п.1, где антитело является мышиным антителом.
5. Способ по п.1, где злокачественная клетка является клеткой меланомы.
6. Способ по п.5, где антитело содержит 9.2.27 или ZME-018.
7. Способ по п.5, где иммунотоксин является scfvMEL-2018 или scfvMEL-2025.
8. Способ по п.1, где клетка находится у пациента.
9. Способ по п.8, где иммунотоксин находится в фармацевтически приемлемой композиции.
10. Способ по п.1, где иммунотоксин доставляется в клетку введением в злокачественную клетку экспрессирующей конструкции, способной экспрессировать этот иммунотоксин.
11. Способ по п.10, где экспрессирующая конструкция является вирусным вектором.
12. Способ по п.11, где вирусный вектор является аденовирусным вектором, аденоассоциированным вирусным вектором, вирусом гепатита, герпесвирусом, лентивирусом, ретровирусом или вирусом коровьей оспы.
13. Способ лечения злокачественных опухолей у пациента, предусматривающий введение этому пациенту эффективного количества композиции, содержащей иммунотоксин, содержащий коровую область токсина гелонина и одноцепочечное антитело, которое специфически нацелено на злокачественную клетку.
14. Способ по п.13, где злокачественная опухоль является злокачественной опухолью предстательной железы, легкого, головного мозга, кожи, печени, молочной железы, лимфоидного органа, желудка, яичек, яичников, поджелудочной железы, костной ткани, костного мозга, головы и шеи, шейки матки, пищевода, глаза, желчного пузыря, почки, надпочечников, сердца, ободочной кишки или крови.
15. Способ по п.13, где иммунотоксин содержит SEQ ID NO:1.
16. Способ по п.13, где антитело нацелено на клетку меланомы.
17. Способ по п.16, где иммунотоксин является scfvMEL-2018 или scfvMEL-2025.
RU2007112876/10A 2001-02-12 2002-02-12 Способ уничтожения злокачественной клетки RU2432358C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26840201P 2001-02-12 2001-02-12
US60/268,402 2001-02-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2003127678/13A Division RU2305684C2 (ru) 2001-02-12 2002-02-12 Модифицированные белки, сконструированные токсины и способы их получения

Publications (2)

Publication Number Publication Date
RU2007112876A true RU2007112876A (ru) 2008-10-20
RU2432358C2 RU2432358C2 (ru) 2011-10-27

Family

ID=23022845

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2007112876/10A RU2432358C2 (ru) 2001-02-12 2002-02-12 Способ уничтожения злокачественной клетки
RU2003127678/13A RU2305684C2 (ru) 2001-02-12 2002-02-12 Модифицированные белки, сконструированные токсины и способы их получения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2003127678/13A RU2305684C2 (ru) 2001-02-12 2002-02-12 Модифицированные белки, сконструированные токсины и способы их получения

Country Status (13)

Country Link
US (5) US7083957B2 (ru)
EP (1) EP1406644A4 (ru)
JP (1) JP2005514000A (ru)
KR (2) KR20080056315A (ru)
CN (1) CN100413885C (ru)
AU (1) AU2002306477B2 (ru)
CA (1) CA2438143C (ru)
IL (1) IL157228A0 (ru)
NO (1) NO20033548L (ru)
NZ (1) NZ527501A (ru)
RU (2) RU2432358C2 (ru)
WO (1) WO2002069886A2 (ru)
ZA (1) ZA200305980B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US20070141135A1 (en) * 2005-06-29 2007-06-21 Balu-Lyer Sathy V Compositions and methods for less immunogenic protein-lipid complexes
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7101977B2 (en) * 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
AU2003217355B2 (en) * 2002-02-07 2009-04-23 University Of Utah Research Foundation Method for creating and using a treatment protocol
WO2003105761A2 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
WO2004071420A2 (en) * 2003-02-05 2004-08-26 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
CA2534565C (en) * 2003-08-05 2012-06-19 The Research Foundation Of State University Of New York Reconstitution medium for protein and peptide formulations
CA2540703C (en) * 2003-10-03 2014-04-08 Board Of Regents, University Of Texas System Methods and compositions for mycoplasma pneumoniae exotoxins
US8586046B2 (en) 2003-10-03 2013-11-19 Board Of Regents, The University Of Texas System Methods and compositions for mycoplasma pneumoniae exotoxins
WO2005052129A2 (en) * 2003-11-25 2005-06-09 Anjin Corporation Diptheria toxin variant
AU2006203850A1 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
WO2006083961A2 (en) * 2005-02-01 2006-08-10 Research Development Foundation Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
WO2006110132A1 (en) * 2005-04-07 2006-10-19 Board Of Regents, University Of Texas System Methods and compositions for mycoplasma pneumoniae exotoxins
US20090104185A1 (en) * 2005-04-07 2009-04-23 Joel Barry Baseman Methods and Compositions for Mycoplasma Toxins
CN100443503C (zh) * 2005-07-18 2008-12-17 四川大学华西医院 人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
EP2311854B1 (en) * 2005-07-29 2013-04-17 The Government of the United States of America, as represented by the Secretary of Health and Human Services Mutated pseudomonas exotoxins with reduced antigenicity
US7662405B2 (en) * 2005-08-09 2010-02-16 The Research Foundation Of State University Of New York Compositions and methods of preparation of liposomal microparticulate IL-12
US20070202593A1 (en) * 2006-02-27 2007-08-30 Research Development Foundation Cell-Targeted IKB and Methods for the Use Thereof
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
AU2007235463B2 (en) * 2006-03-30 2012-11-22 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
EP2010221B1 (en) * 2006-04-21 2012-02-29 mAB-Factory GmbH Antibody-rnase-conjugate
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
US20100068151A1 (en) * 2008-03-11 2010-03-18 Rosenblum Michael G Multimodality molecular imaging with therapeutic conjugates
CN101671397B (zh) * 2008-10-09 2012-09-05 四川大学 抗EGFR单链抗体融合Gelonin重组免疫毒素及其制备方法与用途
AU2011223883B2 (en) 2010-03-01 2015-10-08 Cavion, Inc. Cancer diagnosis and imaging
CA2848311A1 (en) * 2011-09-12 2013-03-21 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
JP6306596B2 (ja) 2012-10-04 2018-04-04 リサーチ ディベロップメント ファウンデーション セリンプロテアーゼ分子および療法
US9388397B2 (en) 2013-02-15 2016-07-12 Research Development Foundation Deimmunized gelonin molecules and therapies
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
US11020486B2 (en) * 2013-11-05 2021-06-01 3M Innovative Properties Company Sesame oil based injection formulations
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
CA2986388C (en) * 2015-06-11 2024-02-27 Genexine, Inc. Modified interleukin-7 protein and uses thereof
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2020006312A1 (en) * 2018-06-28 2020-01-02 Dana-Farber Cancer Institute, Inc. Targeting of multiple antigens with multiplex car t cells in solid and liquid malignancies
US11345967B2 (en) 2019-05-23 2022-05-31 Paradigm Diagnostics Tissue preparation using nuclease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263279A (en) 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
GB1564666A (en) 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof
JPS5686121A (en) 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4522918A (en) 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0118365B1 (en) 1983-03-04 1990-08-29 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
FR2546756B1 (fr) 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4666845A (en) * 1983-12-16 1987-05-19 Sloan-Kettering Institute Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
DE3586216T2 (de) 1984-05-01 1992-12-10 Ciba Corning Diagnostics Corp Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
FR2566271B1 (fr) 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4650674A (en) 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4590071A (en) 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4708930A (en) 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US5032521A (en) 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
DE3585778D1 (de) 1984-12-05 1992-05-07 Salk Inst For Biological Studi Monoklonaler antikoerper, spezifisch fuer brustkrebszelloberflaechenantigen.
CA1339798C (en) 1985-02-01 1998-04-07 Alan N. Houghton Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans
US4888415A (en) 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
DE3581210D1 (de) 1985-03-04 1991-02-07 Dana Farber Cancer Inst Inc Immunotoxin und herstellung.
US6084073A (en) 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0222360A3 (en) 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
DE3685485D1 (de) 1985-12-06 1992-07-02 Cetus Corp Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
US4962188A (en) 1985-12-06 1990-10-09 Cetus Corporation Recombinant ricin toxin A chain conjugates
US4831122A (en) 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
JPS62190200A (ja) 1986-02-17 1987-08-20 Res Dev Corp Of Japan 抗腫瘍蛋白複合体およびその製造方法
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4771128A (en) 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4963354A (en) 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
JPS63190200A (ja) 1987-02-03 1988-08-05 Toyota Motor Corp 電着塗装後処理方法
US4894225A (en) 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
EP0282057A3 (en) 1987-03-11 1990-03-07 The Board Of Regents Of The University Of Michigan Chemo-radio-immuno-conjugates
US4971792A (en) 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US4863726A (en) 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
EP0317641B1 (en) 1987-05-29 1993-03-17 Sagami Chemical Research Center Fused protein containing lymphotoxin
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
ES2054753T3 (es) 1987-09-02 1994-08-16 Ciba Geigy Ag Conjugados de citoquinas con inmunoglobulinas.
US5017371A (en) 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US4867962A (en) 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
CA1329119C (en) 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6750329B1 (en) 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
IE62496B1 (en) 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US6306626B1 (en) 1990-04-27 2001-10-23 Research Development Foundation Anti-IgM monoclonal antibodies and methods of their use
IE912716A1 (en) 1990-08-14 1992-02-26 Res Dev Foundation Protein Structure of the Plant Toxin Gelonin
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
ATE170630T1 (de) * 1990-12-05 1998-09-15 Novo Nordisk As Proteine mit geänderten epitopen und verfahren zur deren herstellung
CA2074825C (en) 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
RU2142015C1 (ru) 1991-09-06 1999-11-27 Рисерч Дивелопмент Фаундейшн Фрагмент днк, кодирующий белок гелонина, и способ его получения, вектор, обеспечивающий экспрессию белка гелонина, рекомбинантный штамм e.coli - продуцент белка гелонина
US5837491A (en) 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6599505B1 (en) 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
JPH08510642A (ja) 1993-05-12 1996-11-12 ゾマ コーポレイション ゲロニンおよび抗体から成る免疫毒素
US5851829A (en) 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5942230A (en) 1994-05-06 1999-08-24 The United States Of America As Represented By The Department Of Health And Human Services Composition of immunotoxins and retinoids and use thereof
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
IL116559A (en) 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
US5851815A (en) * 1996-03-19 1998-12-22 Idun Pharmaceuticals, Inc. MCH4 and MCH5, apoptotic proteases
IL118570A (en) 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
HUP0002317A3 (en) 1997-02-28 2001-11-28 Boehringer Ingelheim Pharma Self-regulated apoptosis of inflammatory cells by gene therapy
EP0893493A3 (de) 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
ATE294865T1 (de) * 1998-02-04 2005-05-15 Thromb X N V Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance'
TR200002496T2 (tr) 1998-02-27 2000-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Gen Terapisinde Ateşli Hücrelerin Kendinden Ayarlı Apoptosisi.
US6645490B2 (en) 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6140066A (en) 1998-03-24 2000-10-31 Lorberboum-Galski; Haya Methods of cancer diagnosis using a chimeric toxin
EP1066404A4 (en) 1998-04-03 2004-04-07 Invitrogen Corp METHOD FOR PRODUCING LIBRARIES OF EXPRESSABLE GENE SEQUENCES
WO1999051620A1 (en) 1998-04-03 1999-10-14 Invitrogen Corporation Libraries of expressible gene sequences
US20040009477A1 (en) 1998-04-03 2004-01-15 Invitrogen Corporation Methods for producing libraries of expressible gene sequences
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
CU22732A1 (es) * 1998-08-14 2002-02-28 Ct Ingenieria Genetica Biotech Mutantes de estreptoquinasa
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP1254167A2 (en) * 2000-01-06 2002-11-06 Monsanto Technology LLC Preparation of deallergenized patatin proteins and patatin permutein proteins
ES2292587T3 (es) 2000-04-22 2008-03-16 Pharmedartis Gmbh Agentes apoptoticos.
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
GB0116047D0 (en) 2001-06-29 2001-08-22 Implyx Ltd Peptide motif for therapy
US7101977B2 (en) 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
WO2003105761A2 (en) 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof

Also Published As

Publication number Publication date
IL157228A0 (en) 2004-02-19
EP1406644A4 (en) 2005-03-16
NZ527501A (en) 2006-04-28
RU2003127678A (ru) 2005-01-20
US20070036780A1 (en) 2007-02-15
AU2002306477B2 (en) 2008-07-10
CN1512888A (zh) 2004-07-14
ZA200305980B (en) 2007-01-31
US20080292544A1 (en) 2008-11-27
WO2002069886A3 (en) 2004-01-22
US7741278B2 (en) 2010-06-22
CN100413885C (zh) 2008-08-27
US8138311B2 (en) 2012-03-20
NO20033548D0 (no) 2003-08-11
CA2438143A1 (en) 2002-09-12
US7943571B2 (en) 2011-05-17
KR20040022208A (ko) 2004-03-11
US20100247518A1 (en) 2010-09-30
NO20033548L (no) 2003-10-10
WO2002069886A2 (en) 2002-09-12
US7285635B2 (en) 2007-10-23
RU2305684C2 (ru) 2007-09-10
KR20080056315A (ko) 2008-06-20
US20110288275A1 (en) 2011-11-24
US7083957B2 (en) 2006-08-01
EP1406644A2 (en) 2004-04-14
US20030176331A1 (en) 2003-09-18
RU2432358C2 (ru) 2011-10-27
CA2438143C (en) 2010-01-12
JP2005514000A (ja) 2005-05-19

Similar Documents

Publication Publication Date Title
RU2007112876A (ru) Модифицированные белки, сконструированные токсины и способы их получения
HRP20200383T1 (hr) Ciljana vezna sredstva protiv b7-h1
DE60134178D1 (de) Trp8 krebsmarker
RU2008130893A (ru) Адипогенные аденовирусы как биомаркеры заболеваний
KR930702526A (ko) 특이적 결합제
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
DE60044665D1 (de) Her2/neu fusionsproteine
DE69834824D1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
PT1718737E (pt) Anticorpos que modificam doenças cancerosas
MY137078A (en) Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors.
ES2394643T3 (es) Anticuerpos que modifican la enfermedad cancerosa
Terazaki et al. An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice
ATE287958T1 (de) Verbesserte krebstherapie
US20050226882A1 (en) Method and multicomponent conjugates for treating cancer
ATE350661T1 (de) Diagnostischer und therapeutischer einsatz von antikörpern gegen den urokinase-rezeptor
Aquino et al. Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells.
CN113755495B (zh) 基因编辑技术在治疗癌症中的应用
Mao et al. P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates
RU98118574A (ru) Метод уничтожения нежелательных клеток-мишеней
JPH06501837A (ja) メラノーマに対する腫瘍ワクチンとしてのｇｐ７５
Kwon et al. In vivo antitumor effect of herpes simplex virus thymidine kinase gene therapy in rat hepatocellular carcinoma: feasibility of adenovirus-mediated intra-arterial gene delivery
Suntharalingam et al. The use of concurrent chemotherapy with high-dose radiation before surgical resection in patients presenting with apical sulcus tumors.
CN105924531A (zh) 一种抗il-4r单链抗体与蜂毒肽融合蛋白及其应用
ES2306677T3 (es) Procedimiento para la produccion de anticuerpos anticancerosos citotoxicos.
KR20180059547A (ko) 항종양 조성물

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170213